These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35724773)

  • 1. Acute and Late Adverse Effects of Prostate-Only or Pelvic Stereotactic Radiation Therapy in Prostate Cancer: A Comparative Study.
    Murthy V; Adsul K; Maitre P; Singla A; Singh P; Panigrahi G; Raveendran V; Phurailatpam R
    Int J Radiat Oncol Biol Phys; 2022 Oct; 114(2):275-282. PubMed ID: 35724773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate.
    Singh M; Maitre P; Krishnan A; Adsul K; Mini Sreekumar S; Chauhan H; Bishnu PN; Phurailatpam R; Singh P; Kamble D; Bakshi G; Pal M; Arora A; Misra A; Prakash G; Murthy V
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(4):1011-1020. PubMed ID: 38908410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Results of Extreme Hypofractionation Using Stereotactic Body Radiation Therapy for High-risk, Very High-risk and Node-positive Prostate Cancer.
    Murthy V; Gupta M; Mulye G; Maulik S; Munshi M; Krishnatry R; Phurailatpam R; Mhatre R; Prakash G; Bakshi G
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):442-447. PubMed ID: 29571936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
    Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
    Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
    Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
    Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
    Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes.
    Faria S; Duclos M; Cury F; Patrocinio H; Souhami L
    Cancer Radiother; 2024 Apr; 28(2):159-163. PubMed ID: 38548531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer.
    Telkhade T; Murthy V; Kanala TS; Mathew JM; Phurailatpam R; Mokal S; Chourasiya D; Panigrahi G; Krishnatry R
    Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):172-180. PubMed ID: 33214044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
    Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
    Greco C; Pares O; Pimentel N; Louro V; Santiago I; Vieira S; Stroom J; Mateus D; Soares A; Marques J; Freitas E; Coelho G; Seixas M; Lopez-Beltran A; Fuks Z
    JAMA Oncol; 2021 May; 7(5):700-708. PubMed ID: 33704378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial.
    Maas JA; Dobelbower MC; Yang ES; Clark GM; Jacob R; Kim RY; Cardan RA; Popple R; Nix JW; Rais-Bahrami S; Fiveash JB; McDonald AM
    Pract Radiat Oncol; 2023; 13(5):466-474. PubMed ID: 37268193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials.
    Leeman JE; Chen YH; Catalano P; Bredfeldt J; King M; Mouw KW; D'Amico AV; Orio P; Nguyen PL; Martin N
    Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):75-82. PubMed ID: 34711459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
    Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study.
    Jorgo K; Polgar C; Stelczer G; Major T; Gesztesi L; Agoston P
    Radiol Oncol; 2021 Jul; 55(4):474-481. PubMed ID: 34253001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
    Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
    Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
    Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
    JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.